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Kuolleisuus ja hoitomyöntyvyys adaptiivisessa servo-ventilaatiohoidossa 
uniapneaa sairastavilla potilailla 
Suomenkielinen tiivistelmä opinnäytetyöstä ”Mortality and Compliance in Adaptive 
Servo-Ventilation Treatment for patients with Sleep Apnea” 
 
 Katja Pelkonen, MB, Faculty of Medicine and Life Sciences, University of 
Tampere, Tampere, Finland 
 
Tämän opinnäytteen alkuperäisyys on tarkastettu Turnitin OriginalityCheck-ohjelmalla Tampereen 
yliopiston laatujärjestelmän mukaisesti. 
 
 
Tausta 
Unenaikaiset hengityshäiriöt ovat yleisiä sydämen vajaatoimintaa sairastavilla potilailla (1) ja jopa 70 
prosentilla sydämen vajaatoiminta –potilaista on joko obstruktiivinen tai sentraalinen uniapnea (2-5). 
Sentraalisen uniapean esiintyvyys on alle prosentti terveessä väestössä (1), mutta sydämen vajaatoimintaa 
sairastavilla potilailla se on yleinen sairaus ja jopa 50 prosentilla näistä potilaista todetaan sentraalinen 
uniapnea (1,3,6). Sentraalisen uniapnean syytä ei tarkkaan tunneta, mutta sen on ajateltu johtuvan lähinnä 
erityisesti sydämen vajaatoiminnassa esiintyvästä elimistön lisääntyneestä reaktiosta hiilidioksidin 
osapaineelle verenkierrossa sekä verenkierron muutoksista alentuneeseen sydämen minuuttitilavuuteen 
liittyen. (1,2,5-9) 
 
Adaptiivinen servo-ventilaatio (ASV) on ei-invasiivinen ventilaatiohoito, joka on suunniteltu hoitamaan sekä 
obstruktiivista uniapneaa jatkuvalla positiivisella painetuella, että sentraalista uniapneaa vaihtelevalla 
hengityksen painetuella (2,3,6,9,10). SERVE-HF –tutkimus (11) oli ensimmäinen laaja monikansallinen 
tutkimus, joka tutki ASV-hoidon etuja sydämen vajaatoimintaa sekä sentraalista uniapneaa sairastavilla 
potilailla. Keväällä 2015 julkaistujen tutkimustulosten mukaan ASV-hoito lisäsi kuolleisuutta tässä 
potilasryhmässä potilailla, joilla sydämen vasemman kammion ejektiofraktio (LVEF) oli alle 45%. 
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Tampereen yliopistollisen sairaalan uniyksikkö on hoitanut kaiken kaikkiaan 50 potilasta ASV-hoidolla. Tätä 
potilasryhmää ja hoidon etuja ei ole aiemmin tutkittu Tampereen yliopistossa. Suunnittelimme ja toteutimme 
retrospektiivisen tutkimuksen real life –tutkimusasetelmassa näistä 50 hoitoa saaneesta potilaasta. Tutkimme 
ASV-hoidon etuja, hoidon aloittamisen indikaatioita sekä hoitoa saanutta potilasryhmää.  
 
Metodit 
Kävimme läpi kaikki Tampereen yliopistollisen sairaalan uniyksiköstä vuosina 2002 – 2016 ASV-hoitoa 
saaneiden potilaiden potilaskertomukset ja keräsimme tiedot potilaiden demografiikasta, ASV-hoidon 
aloituksen indikaatioista, lopettamisen syistä, hoitomyöntyvyydestä, hoidon onnistumisesta ja 
kuolleisuudesta seuranta-aikana. 
 
Tulokset 
Pää-indikaatio ASV-hoidon aloittamiselle oli sekamuotoinen obstruktiivinen ja sentraalinen uniapnea. 
Hoitomyöntyvyys oli hyvä; keskimääräinen käyttöaika yössä oli lähes kuusi tuntia ja yli 65 prosenttia 
potilasta oli tyytyväisiä hoitoon. Yli 61 prosentilla potilaista oli sydämen vajaatoiminta ja näillä potilailla EF 
alentui lievästi lähes kuuden vuoden seuranta-aikana (50.9% seurannan alussa, 46.1% viimeisin tulos 
seurannan aikana, P = 0,25). Unen laatu parani lievästi ja päivänaikainen väsymys lievittyi Epworth 
Sleepiness Scale –kyselyllä mitattuna (ESS, 8.1 pistettä alussa, 6.7 pistettä viimeisin mittaus seurannan 
aikana, P = 0.036). Apnea-hypokapnea-indeksi parani huomattavasti ja merkitsevästi ASV-hoidolla (49.6 
ennen hoitoa, 4.9 viimeisin mittaus hoidon aikana, P = .000). Kuolleisuus oli 8 prosenttia lähes kuuden 
vuoden seuranta-aikana. 
 
Johtopäätös 
Real life –tutkimusasetelmassa sydämen vajaatoimintaa ja sentraalista uniapneaa sairastavilla potilailla, joilla 
EF oli vähintään 45%, ASV-hoito näyttää parantavan apnea-hypokapnea-indeksiä, parantavan unenlaatua 
sekä vähentävän päivänaikaista väsymystä. Hoitomyöntyvyys on hyvä ja kuolleisuus matala. 
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ABSTRACT 
 
Introduction. Adaptive servo-ventilation (ASV) is designed to treat both obstructive sleep apnea (OSA) 
with continuous pressure support and central sleep apnea (CSA) with varying inspiratory pressure support. A 
recent multinational trial to study the benefits of ASV treatment in subjects with heart failure (HF) and CSA 
showed increased mortality with ASV treatment in subjects with ejection fraction (EF) ≤ 45%. Our aim was 
to conduct a real-life retrospective analysis on the benefits, compliance and mortality among subjects with 
CSA treated with ASV where the treatment had been discontinued in subjects with EF < 45 %. 
Methods. Medical records of all 50 subjects treated with ASV in Tampere University Hospital Sleep Unit 
during years 2002 - 2016 were reviewed and data of subject characteristics, ASV-treatment details and 
outcomes were collected. 
Results. Main reason for prescribing ASV-treatment was OSA-CSA. Compliance for treatment was good. 
Over 61% of the subjects had HF and for those there was a slight but not significant impairment in EF (50.9 
to 46.1, P = 0,25) during almost six years of follow up. There was a mild improvement in quality of sleep 
and daytime fatigue measured with the Epworth Sleepiness Scale (ESS, 8.1 to 6.7, P = 0.036). Apnea - 
hypocapnea (AH) -index improved extensively and significantly with ASV treatment (49.6 to 4.9, P = .000). 
Mortality was 8% during almost six years follow up. 
Conclusion. In a real life setting in subjects with HF and CSA-CSR with an EF of at least 45% ASV 
treatment seems to be improving AHI, quality of sleep and decreasing daytime fatigue. The compliance for 
treatment is good and mortality is low. 
 
Keywords 
Sleep Apnea, Central Sleep Apnea, Heart Failure, Noninvasive Ventilation, Adaptive Servo-Ventilation, 
Mortality, Compliance 
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Introduction 
Sleep disordered breathing (SDB) is a common syndrome in patients with heart failure (HF) (1) and even up 
to 70 % of the HF patients have either obstructive sleep apnea (OSA) or central sleep apnea – Cheyne–
Stokes respiration (CSA-CSR) (2-5). The incidence of CSA-CSR is under 1% in healthy population (1), but 
amongst HF patients with more severe disease (NYHA III-IV) CSA-CSR is a common condition with 21 - 
50% suffering from it (1,3,6). HF itself can cause similar symptoms as SDB (2,5,6), but there is also a 
hypothesis that CSA-CSR might even be a compensatory mechanism in severe HF (7-9). The severity of HF 
correlates to the severity of CSA-CSR, but on the other hand CSA-CSR accelerates the progression of HF, 
decreases the time to heart transplantation, and increases mortality (5,6,8,9). CSA-CSR and OSA are 
conditions highly underdiagnosed among patients with HF (2,5,6). The presence of SDB with HF is 
associated with worsened prognosis and increased mortality (10). 
 
The pathophysiology causing CSA-CSR is still somewhat unknown. It seems to be mainly caused by the 
body’s increased reaction to partial pressure of CO2 and changes in circulation because of decreased cardiac 
output in HF. Lung to brain circulatory delay is prolonged in HF and the chemical regulation, caused by the 
partial pressure of CO2 in blood affecting the baroreceptors in chest and brain, is secondarily delayed. The 
partial pressure of carbon dioxide may fluctuate during sleep. In HF the increased sympathetic activity is 
responsible for the increased sensitivity of chemoreceptors to PaCO2. In this case the negative-feedback 
system, that controls breathing, elicits a large ventilatory response when the partial pressure of carbon 
dioxide rises. The consequent hyperventilation drives the partial pressure of carbon dioxide below the apneic 
threshold resulting in central apnea. As a result of the apnea, the partial pressure of carbon dioxide rises 
again, which leads to an increased ventilation. In this way cycles of central apnea and hyperventilation recur 
during sleep. (1-3,5-7,9) 
 
The treatment of SDB in patients with HF has been shown to increase the time to heart transplantation and 
improve NYHA functional class (11) but the treatment of CSA-CSR is still controversial. Since CSA-CSR is 
a result of HF or even compensatory to it, the optimal treatment of HF is essential in treating CSA-CSR (12). 
Adaptive servo-ventilation (ASV) is a non-invasive ventilation therapy designed mainly to treat CSA-CSR 
	 9	
(9). ASV delivers a baseline continuous positive airway pressure and variable increase in inspiratory 
pressure. ASV devices are equipped with sensors that can detect central apneas and the algorithm used by 
these machines assesses the amplitude and frequency in airflow and compares these with the target values 
determined to match the patient’s minute ventilation during stable breathing. The goal of ASV therapy is to 
break the periodic breathing cycle. (2,3,6,9,13) Multiple studies have suggested ASV as a beneficial 
treatment for symptoms of CSA-CSR, but none have proved it to be curative. Studies show improvements in 
quality of life, EF, oxygen uptake, 6-min walking distance –test, AHI-index, sleep fragmentation and sleep 
efficiency. ASV has been shown to moderate the sympathetic adrenergic tone by decreasing natriuretic 
peptide concentration, urinary metadrenaline excretion and ventricular premature complexes. There are 
results in decreasing daytime sleepiness and heart failure symptoms, reducing hospital admissions and 
increasing oxygen saturation. (10,14-24) 
 
The SERVE-HF trial (25), sponsored by ResMed, was the first large multinational trial to study the benefits 
of ASV treatment. After a 12-months follow-up the results showed that all-cause and cardiovascular 
mortality were both increased with this therapy. ASV had no significant effect on the primary end point 
(death from any cause, lifesaving cardiovascular intervention e.g. cardiac transplantation, resuscitation after 
sudden cardiac arrest, unplanned hospitalization for worsening HF) in subjects who had HF with reduced EF 
and predominantly CSA. After the SERVE-HF report several institutes cancelled trials studying ASV in 
treating CSA-CSR. A Field Safety Notice (26) was issued by ResMed in 2015 stating that ASV therapy is 
contraindicated with HF patients with a reduced EF. A secondary multistate modelling analysis of SERVE-
HF data (8) showed an increased risk of both cardiovascular death without previous hospital admission and 
cardiovascular death after a life-saving event in the group receiving ASV versus the control group. Updated 
Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline were released based on meta-
analyses in May 2016 (27). A Standard level recommendation against the use of ASV to treat subjects 
suffering from congestive HF and CSA-CSR with a EF of ≤ 45% was suggested. 
 
Tampere University Hospital Sleep Unit has been treating a total of 50 subjects with Adaptive Servo-
Ventilators. After the Field Safety Notice and the new AASM recommendations were released a cardiologist 
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was consulted with all the subjects suffering from HF and treated with ASV in Tampere University Hospital. 
ASV-treatment was discontinued and replaced with more suitable treatment such as CPAP with subjects 
suffering from severe HF (EF ≤ 45%). So far the subjects using and the benefits of ASV-treatment have not 
been studied in Tampere University Hospital. A retrospective study of the 50 subjects using or having used 
the ASV-treatment was conducted to describe the indications for prescribing ASV treatment and the subject 
group using this treatment, and to evaluate the benefits of ASV in treating CSA-CSR and HF. 
 
 
Methods 
A retrospective study of all the subjects using or having used the ASV-treatment (BiPAP AutoSV Philips 
Respironics, © Murrysville Pennsylvania U.S. or AutoSet CS-A Resmed, © Resmed Australia) in Tampere 
University Hospital Sleep Unit was conducted. Medical records of all 50 subjects treated with ASV during 
years 2002 - 2016 were reviewed. The study was approved by the ethics committee of Tampere University 
Hospital. The basic demographics and comorbidities of the subjects were collected from the medical records. 
A starting date and a reason for initiating ASV-treatment and possible end date with a reason for ending 
ASV-treatment were recorded. Compliance for the treatment was studied with analyzing the length of ASV 
treatment, nightly hours of using the ventilator and also personal experience of satisfaction with the 
treatment. The benefits of ASV treatment considering the quality of sleep and daytime fatigue were studied 
with obtaining the result of Epworth Sleepiness Scale (ESS) (28) questionnaire before ASV-treatment and 
latest result during treatment. Information of AH-index before treatment, during possible CPAP treatment 
before ASV-treatment and during ASV-treatment was obtained to study the effects of the treatment for 
decreasing central apneas and breaking the crescendo-cycle of breathing. The results are presented as mean 
(SD) or n (%) where appropriate. 
 
Statistical analyses of the data were done using the SPSS V23.0 software package (SPSS Inc.). Differences 
in parameters before and during treatment considering the efficiency of ASV-treatment were analyzed using 
the Related-Samples Wilcoxon Signed Rank Test. p Value of < 0.05 was considered significant. 
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Results 
Altogether 50 subjects had been treated with ASV. One subject was excluded from the analysis due to 
insufficient medical record data. Most of the ASV-treated subjects were male, elderly and obese (Table 1). 
Over 61% of the subjects had HF, atrial fibrillation or atrial hypertension and over 30% had type II diabetes 
or coronary arterial disease.  
 
Details of ASV-treatment are presented in Table 2. Main reason for prescribing the treatment was OSA-CSA 
and almost 70% of the subjects were treated with a trial of CPAP-treatment before ASV-treatment.  The 
mean duration of follow-up was almost six years. Compliance for treatment was good: mean nightly use was 
almost six hours and over 65 percent of the subjects were satisfied with the treatment. ASV-treatment was 
discontinued during follow up most frequently because of no compliance to treatment or HF. Mortality 
during study was as low as 8.2%. 
 
The outcome measures related to ASV-treatment are presented in Table 3. AHI was quite high before any 
treatment (49.6/h) and there was a significant but only partial alleviation in those subjects who had been 
treated with a trial of CPAP (28.0/h). However, after treatment with ASV there was an even more profound 
decrease in AHI to normal level. The improvement in ESS-points before treatment and latest results during 
follow up was mild but statistically significant (P = 0.04, Wilcoxon test). The impairment in EF in patients 
with HF from before treatment to latest result during follow up was not significant (P = 0,25, Wilcoxon test). 
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TABLE 1 SUBJECT CHARACTERISTICS OF THE 49 PATIENTS INCLUDED 
 
 
 
 
 
 
 
mean (sd) 
 
 
n (%) 
 
Data available 
n (%) 
 
 
MALES/FEMALES 
  
 
42 (85.7) / 7 (14.3) 
 
 
49 (100) 
 
 
AGE  
 
 
67.1 years (12.7) 
 
 
 
 
 
49 (100.0) 
 
 
BMI 
 
 
32.1 (5.6) 
 
 
 
 
 
47 (96) 
 
 
CURRENT SMOKERS 
  
 
8 (16.3) 
 
 
 
FORMER SMOKERS 
  
 
10 (20.4) 
 
NO MENTION OF 
SMOKING IN PATIENT 
RECORDS 
  
 
31 (63.3) 
 
 
PACK YEARS AMONGST 
CURRENT AND EX 
SMOKERS 
 
 
 
23.5 years (15.9) 
 
 
 
 
 
 
 
15  (30.6) 
 
 
COMORBIDIES 
   
 
 
HEART FAILURE 
  
 
30 (61.2) 
 
 
 
ATRIAL FIBRILLATION 
  
 
28 (57.1) 
 
 
 
STROKE 
  
 
9 (18.4) 
 
 
 
DIABETES MELLITUS TYPE 
II 
  
 
 
15 (30.6) 
 
 
 
CORONARY ARTERY 
DISEASE 
  
 
 
15 (30.6) 
 
 
 
ARTERIAL HYPERTENSION 
  
 
 
29 (59.2) 
 
 
CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
  
 
3 (6.1) 
 
 
 
ASTHMA 
  
 
3 (6.1) 
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TABLE 2 DETAILS OF ASV-TREATMENT 
 
 
 
 
 
mean (sd) 
 
N, total = 49 (%) 
 
Data aivailable, n (%) 
 
DURATION OF FOLLOW UP 
 
5.9 years (16.2) 
 
 
 
49 (100.0) 
 
REASON FOR TREATMENT 
   
49 (100.0) 
 
 
OSA-CSA 
  
 
39 (79.6) 
 
 
 
CSA 
  
 
5 (10.2) 
 
 
 
OSA 
  
 
3 (6.1) 
 
 
 
OTHER SLEEPING DISORDER 
  
 
2 (4.1) 
 
 
CPAP-TREATMENT BEFORE 
ASV-TREATMENT 
  
 
34 (69.4) 
 
 
 
NIGHTLY USE 
 
 
5.8 hours (2.0) 
 
 
 
 
 
39 (79.6) 
 
SUBJECTIVE EXPERIENCE OF 
TREATMENT: 
   
 
45 (76) 
 
 
SATISFIED 
  
 
33 (67.3) 
 
 
 
DISSATISFIED 
  
 
9 (18.4) 
 
 
 
NO DIFFERENCE 
  
 
3 (6.1) 
 
ASV-TREATMENT 
DISCONTINUED DURING 
FOLLOW UP 
  
 
15 (30.6) 
 
 
REASON FOR TREATMENT  
DISCONTINUATION: 
 
   
 
 
NO COMPLIANCE 
  
 
5 (10.2) 
 
 
 
HEART FAILURE 
  
 
4 (8.2) 
 
 
 
NO NEED TO TREAT 
  
 
2 (4.1) 
 
 
 
NO EFFECT 
  
 
1 (2.0) 
 
 
MORTALITY 
 
 
 
4 (8.2) 
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TABLE 3 OUTCOME MEASURES OF ASV TREATMENT 
  
 
Before 
treatment 
 
 
During CPAP-
treatment 
 
During ASV-
treatment, 
latest result 
 
P-value (before 
treatment vs. 
durin Cpap) 
 
P-value (during 
cpap vs. during 
asv) 
 
P-value (before 
treatment vs. 
during ASV) 
AHI 
AVAILABLE 
N (%) 
 
 
43 (87.8) 
 
 
32 (65.3) 
 
 
44 (89.8) 
   
 
AHI 
MEAN (SD) 
 
 
49.6 (19.7) 
 
 
28.0 (16.0) 
 
 
4.9 (4.95) 
 
 
.000 
 
 
.000 
 
 
.000 
EF 
AVILABLE 
N (%) 
 
 
27.0 (55.1) 
  
 
23 (46.9) 
   
 
EF 
MEAN (SD) 
 
 
50.9 (12.4) 
  
 
46.1 (15.6) 
   
 
 .25 
ESS 
AVAILABLE 
N (%) 
 
 
26.0 (53.1) 
     
 
ESS 
MEAN (SD) 
 
 
8.1 (3.96) 
  
 
6.7 (4.8) 
   
 
 .04 
    
 
   
AHI, apnea hypopnea index 
EF, ejection fraction 
ESS, Epworth Sleepiness scale 
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Discussion 
In this retrospective study we found that the main reason for prescribing ASV-treatment was OSA-CSA and 
over 70% of the subjects were treated with trial of CPAP-treatment before ASV-treatment. Compliance for 
treatment was good. Over 61% of the subjects had HF and for those there was a slight but not significant 
impairment in EF during almost 6 years of follow up. There was a mild improvement in quality of sleep and 
daytime fatigue measured with the ESS-questionnaire. AH-index improved extensively and significantly 
with ASV treatment. Mortality was fairly low for an elderly subject group with several comorbidities. 
 
The results of this study must be reflected in the light of the SERVE-HF –study (25). The subjects in our 
study were dominantly male and elderly like in the SERVE-HF and the follow up time was similar, almost 
six years. Comorbidities existed equally. In the ASV group of SERVE-HF study HF was more severe (mean 
EF = 32.2) compared to our subject group (mean EF during treatment = 46.1). According to the most recent 
studies (8,9) CSA is a compensatory mechanism in severe HF rather than a mediator in disease progression. 
SERVE-HF multistate modelling analysis (27) showed that in subjects with EF less than or equal to 30%, 
use of ASV markedly increased the risk of cardiovascular death. The more severe state of HF in SERVE-HF 
ASV group might be one explanation to the higher mortality rate in SERVE-HF ASV group (34.8%) 
compared to the mortality (8.2%) in this study. Also during the follow up ASV treatment was discontinued 
with 8% of the subjects due to severe HF and EF ≤ 45%, which might have affected the low mortality rate 
found in this study. Over two thirds of subjects were treated with a trial of CPAP before ASV and for these 
subjects AH-index decreased significantly treating with ASV compared CPAP. This might indicate to 
treatment emerged CSA, which means that treatment of OSA or sleep apnea in general with CPAP reveals a 
central component. This has been seen in other studies as well (9). The improvement in AHI is aligned with 
other ASV-study results (9). This is to be expected since ASV-devices treat both OSA with continuous 
pressure support and CSA with varying inspiratory pressure support, breaking the crescendo-cycle of 
breathing and in this way diminishing apneas and hypopneas. Improvement in ESS points was also seen in 
SERVE-HF-study (25). Daytime fatigue and quality of sleep have shown improvement in several studies 
with ASV-treatment (9,17).  
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It is still unknown whether CSA-CSR is a marker or in fact a mediator in the progress of HF and so 
according to the recent studies and this retrospective report it remains unclear how ASV treatment affects the 
progress of HF (8,9). In another Scandinavian retrospective study (29) 18 months of ASV treatment did not 
significantly affect cardiovascular death, combined cardiovascular death or hospital admissions in subjects 
with CSA and HF, but there was a trend towards better combined outcome. In the recent CAT-HF-trial (30) 
in hospitalized HF patients with moderate-to-severe sleep apnea, adding ASV to optimal medical treatment 
did not improve 6-month cardiovascular outcomes, but according to pre-specified subgroup analysis a 
positive effect of ASV in preserving EF for subjects with HF was suggested. More data on prognostic 
relevance of CSA-CSR, changes in cardiac parameters during ASV treatment and indication for treatment is 
needed. The ongoing ADVENT-HF trial (31) is looking whether ASV can reduce the rate of cardiovascular 
hospitalizations and death in subjects with HF and sleep apnea. So far, no effective alternative treatment to 
CSA for patients with HF and EF ≤ 45% is available. Unilateral phrenic nerve stimulation that improves 
CSA, daytime fatigue and sleep quality might be a promising treatment alternative. However, studies of 
phrenic nerve stimulation and cardiovascular outcomes are still missing (32).  
 
The study being a retrospective analysis causes limitations. The subjects were not examined and interviewed 
with a similar standardized manner but the data was collected from medical records manually. The clinical 
findings such as EF and AHI were not measured at every visit or in the same stage of treatment for every 
subject. Sample size in our study was small, only 50 subjects were treated with ASV and included in the 
study. However, this was a real life –study without exclusion criteria, describing the use of ASV-treatment in 
subjects using it at home during almost six years of follow up, which can be considered as a strength for the 
study.  
 
In conclusion in a real life setting, the results of ASV treatment in subjects with HF and CSA-CSR with an 
EF of at least 45% are quite satisfying: for these subjects ASV treatment seems to be improving AHI, quality 
of sleep and decreasing daytime fatigue. The compliance for treatment is good and mortality is low.  
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